Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity.
Engineered antibody therapeutics have provided new treatment options in cancer. Genetic evidence in man and in the mouse suggests that Fc receptor (FcR) engagement contributes mechanistically to the therapeutic activity of naked antibodies. Preferential activation of activating FcRs and limited engagement of inhibitory FcRs enhance tumor responses in mouse models. Thus, engineered Fc domains with favorable affinities for specific FcR types may prove to be clinically superior.
Clynes
Raphael
R
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA. rc645@columbia.edu
D000818:Animals; D000906:Antibodies; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009895:Opsonin Proteins / Q000276:immunology / Q000627:therapeutic use; D015202:Protein Engineering / Q000379:methods; D011961:Receptors, Fc / Q000235:genetics / Q000276:immunology
D000906:Antibodies; D000912:Antibodies, Neoplasm; D009895:Opsonin Proteins; D011961:Receptors, Fc